Amyris delivers high-performance alternatives to petroleum, plant and animal-based products across a wide range of consumer and industry segments. Our products offer customers a way to reduce environmental impact with No Compromise™ in performance or availability. We are making better chemistry biologically.

Paradigm Capital Biosynthesis Conference

Apr 15, 2019
1:25 PM EDT

Additional Information

Amyris will discuss its previously disclosed cannabinoid development, licensing and commercialization agreement containing $300 million of R&D and milestone payments and a long-term royalty stream during the presentation and 1X1 investor meetings. Due to the format of this inaugural event, the presentation is not being webcast.